ASCO
Novartis releases new data across oncology and haematology pipelines
May 21, 2025Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
ISA Pharmaceuticals highlights positive clinical data at ASCO
June 6, 2023Research and Development ASCO, Cancer, HPV, ISA Pharmaceuticals, Oncology
Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …
AstraZeneca shares oncology data at ASCO 2023
May 25, 2023Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology
AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on …
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
“Underwhelming” drug data devastates Nektar, shares fall by 42%
June 5, 2018Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma
Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …
Janssen debuts promising new cancer data at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma
Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …
Roche’s breast, lung cancer offerings fail to impress at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …
Unprecedented CAR-T data shows 100% response rate
June 7, 2017Research and Development ASCO, CAR T, CAR-T
Researchers celebrated a world-first at the American Society of Clinical Oncology conference, revealing data which showed that, in a study …
New targeted therapy promises strong response rate across 17 cancer types
June 5, 2017Research and Development, Sales and Marketing ASCO, Cancer, Loxo Oncology, oncology
Loxo Oncology’s lead therapy larotrectinib made a big impact at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, …
MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival
June 8, 2016Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda
Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study
June 7, 2016Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social
Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …
The Pharmafocus ASCO round-up
June 7, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus
As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
Amgen showcases positive Phase III multiple myeloma drug at ASCO
June 7, 2016Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma
Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …
Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
